Association of Galectin-3 and Fibrosis Markers with Long-Term Cardiovascular Outcomes in Patients with Heart Failure, Left Ventricular Dysfunction, and Dyssynchrony: Insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial
Open Access
- 1 January 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 14 (1) , 74-81
Abstract
Aims: Circulating biomarkers of collagen turnover reflect extracellular cardiac matrix (ECCM) remodelling. The extent to which the success of cardiac resynchronization therapy (CRT) is influenced by the degree of cardiac fibrosis and whether CRT can influence matrix remodelling has yet to be studied. Our aim was to determine, in patients with heart failure (HF) and cardiac dyssynchrony, whether ECCM biomarkers are influenced by CRT and can predict cardiovascular outcomes and response to CRT. Methods and results: Serum levels of ECCM biomarkers [galectin-3 (Gal-3), N-terminal propeptides of type I and III procollagens (PINP and PIIINP), type I collagen telopeptide (ICTP), and matrix metalloproteinase 1 (MMP-1)] were measured in 260 patients, in a substudy of CARE-HF, a randomized controlled trial which evaluated the effects of CRT in patients with left ventricular systolic dysfunction and cardiac dyssynchrony. ECCM biomarkers did not change throughout the 18-month follow-up period. In age- and gender-adjusted analyses, Gal-3 and PIIINP were associated with death or HF hospitalization. In a further multivariate model, Gal-3 >30 ng/mL was associated [OR (95% CI):2.98 (1.43–6.22), P = 0.004] with death or HF hospitalization, along with left ventricular end-systolic volume >200 mL [3.42 (OR: 1.65–7.10), P = 0.001]. The outcome death or left ventricular ejection fraction (LVEF) ≤35% was associated with MMP-1 [≤3 ng/mL: 3.04 (1.37–6.71), P = 0.006]. No significant interaction was observed between the tested biomarkers and the treatment group. Conclusions: Increased Gal-3 and PIIINP, and low MMP-1 are associated with adverse long-term cardiovascular outcomes but did not predict response to CRT. CRT did not favourably affect serum concentrations of ECCM markers.Keywords
This publication has 33 references indexed in Scilit:
- Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpressionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fractionAnnals of Medicine, 2010
- Galectin-3, Cardiac Structure and Function, and Long-Term Mortality in Patients with Acutely Decompensated Heart FailureEuropean Journal of Heart Failure, 2010
- Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF studyClinical Research in Cardiology, 2010
- Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart FailureCirculation, 2009
- Plasma Biomarkers of Myocardial Fibrosis and Remodeling in Terminal Heart Failure Patients Supported by Mechanical Circulatory Support DevicesThe Journal of Heart and Lung Transplantation, 2008
- Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal FibrosisThe American Journal of Pathology, 2008
- Matrix metalloproteinase‐1 and its inhibitor, TIMP‐1, in systolic heart failure: relation to functional data and prognosisJournal of Internal Medicine, 2007
- Excess Aldosterone under Normal Salt Diet Induces Cardiac Hypertrophy and Infiltration via Oxidative StressHypertension Research, 2005
- Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac DysfunctionCirculation, 2004